XNAS · Diagnostics & Research
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$369.39+0.84%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
54/100
Moderate
Score components
TickerWhale View
Natera scores 54 out of 100 overall, which we rate moderate. Technical is its strongest area and Valuation its weakest.
What helps
- Technical
- Quality & growth
- Risk
What to watch
- Valuation
Quality & growth
30%55Positive
- Revenue growth 37.8%
- EPS growth n/a
Valuation
25%4Weak
- P/E -275.1
- EV/Sales 19.2
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
#239 by market cap in our coverage · ~6,140 employees · Listed 2015-07-02 · www.natera.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#79 / 139sector rank by TickerWhale Score
TickerWhale Score 54 vs sector average 55.1 (-1.1)
Revenue growth (industry)Top 16%
Gross margin (industry)Top 12%
Return on equity (industry)Top 94%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
99/100Strong vs universe
Ranks 99th of 100 covered names on our technical composite — the composite itself scores 83/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
5 buy · 3 sell · 0 neutral of 8 votes
TickerWhale rates NTRA's technical setup strong — 99th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+53.5%
- vs 50-day+21.4%
Momentum
Weak
- RSI (14)74 · sell
- Stochasticsell
- CCIbuy
- Williams %Rsell
Trend
Constructive
- ADX (14) trend strength41· trending
- MACD (12,26,9)buy(histogram 2.271)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 4 buy · 3 sell · 0 neutral.
Result — 5 buy vs 3 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)-275.1 · TTM loss
- P/S (TTM)19.6
- P/B29.1
- EV/EBITDA—
- EV/Sales19.2
- PEG—
Profitability & returns
- Gross margin65.2%
- Net margin-7.1%
- ROE-10.7%
- Debt/Equity0.04
Growth
- Revenue growth (YoY)37.8%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $52.9B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NTRACurrentNatera | 54 | 83 | -275.1 | — | 29.1 | 19.2 | $369.39 | +0.84% | +37.8% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.